NCT01896284 - Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

June 30, 2015

Conditions

Wet Macular Degeneration

Interventions

DRUG

0.5mg aflibercept

0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.

Trial Locations (1)

Barcelona Macula Foundation, Barcelona